Challenges and opportunities of defining clinical leptin resistance.
The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA. mgmyers@umich.edu
Martin G
MG
Myers
Steven B
SB
Heymsfield
Carol
C
Haft
Barbara B
BB
Kahn
Maren
M
Laughlin
Rudolph L
RL
Leibel
Matthias H
MH
Tschöp
Jack A
JA
Yanovski
D015975:Consensus Development Conferences, NIH as Topic; D004351:Drug Resistance / Q000502:physiology*; D006801:Humans; D020738:Leptin / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D009316:National Institutes of Health (U.S.); D009765:Obesity / Q000473:pathology*; D014481:United States
D020738:Leptin